Predictive value of copeptin as a severity marker of community-acquired pneumonia

Gamal Baheeg Mohamed, Madeha Abdellah Saed, Abdelhakeem Abdelmohsen Abdelhakeem, Kalid Salah, Abdelrahman Mamdouh Saed, Gamal Baheeg Mohamed, Madeha Abdellah Saed, Abdelhakeem Abdelmohsen Abdelhakeem, Kalid Salah, Abdelrahman Mamdouh Saed

Abstract

Background: Pneumonia is the leading cause of death in children. Few studies have explored the predictive value of copeptin in pediatric pneumonia.

Aim: This study aimed to assess the role of copeptin as a marker of severity of community-acquired pneumonia (CAP).

Methods: This prospective case-control study was carried out at Minia University Children's Hospital in Minia (Egypt) from January to December 2016. Eighty children aged from 2 months to 42 months were enrolled in this study and were classified into group 1 (40 children with clinical, laboratory and radiological evidence of pneumonia) and group 2 (40 apparently healthy control). Serum copeptin level was assayed for all enrolled children.

Results: Mean serum copeptin level was significantly higher in pneumonic patients (985.7±619) pg/ml compared to controls (519±308.2) pg/ml (p<0.001). Serum copeptin was significantly elevated in survivors of pneumonia more than non-survivors (p=0.001). Also, copeptin was significantly higher in the group of non-survivors (1811.8±327.1) compared to 745.4±472.5 for survivors (p=0.01). There was a significant positive correlation between serum copeptin levels and the degree of respiratory distress (p=0.02).

Conclusion: Copeptin seems a reliable and available predictor marker for assessing the severity and prognosis of pediatric community acquired pneumonia.

Keywords: Community acquired pneumonia; Copeptin; Outcome.

Conflict of interest statement

Conflict of Interest: There is no conflict of interest to be declared.

Figures

Figure 1
Figure 1
ROC curve analysis Copeptin level in CAP patients.

References

    1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375(9730):1969–87. doi: 10.1016/S0140-6736(10)60549-1.
    1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2(1):25–32. doi: 10.1016/S1473-3099(01)00170-0.
    1. Otapchuk M, Roberts D, Haddy R. Community-Acquired Pneumonia in Infants and Children. Am Fam Physician. 2004;70(5):899–908.
    1. Land H, Schutz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature. 1982;295(5847):299–303. doi: 10.1038/295299a0.
    1. Katan M, Müller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care. 2008;12(2):117. doi: 10.1186/cc6799.
    1. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit CareMed. 2010;182:1426–34. doi: 10.1164/rccm.201003-0415OC.
    1. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397] Crit Care. 2006;10(3):R96. doi: 10.1186/cc4955.
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112–9. doi: 10.1373/clinchem.2005.060038.
    1. Michels M, Djamiatun K, Faradz SM, Koenders MM, de Mast Q, van der Ven AJ. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections. J Clin Virol. 2011;50(1):8–12. doi: 10.1016/j.jcv.2010.09.008.
    1. Sarda Sanchez M, Hernandez JC, Hernandez-Bou S, Teruel GC, Rodriguez JV, Cubells CL. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study. BMC Res Notes. 2012;5:363. doi: 10.1186/1756-0500-5-363.
    1. Miyaji1 Y, Sugai K, Asako N, Miho K, Shoichi N, Hiroyuki T, et al. Pediatric Respiratory Severity Score (PRESS) for Respiratory Tract Infections in Children. Austin Virology and Retrovirology. 2015;1(1):1–7.
    1. Rudan I, O’Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3(1):010401. doi: 10.7189/jogh.03.010401.
    1. Muller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Investig. 2007;37(2):145–52. doi: 10.1111/j.1365-2362.2007.01762.x.
    1. Du JM, Sang G, Jiang CM, He XJ, Han Y. Relationship between plasma copeptin levels and complications of community-acquired pneumonia in preschool children. Peptides. 2013;45:61–5. doi: 10.1016/j.peptides.2013.04.015.
    1. Wrotek A, Jackowska T. Hyponatremia in children hospitalized due to pneumonia. Adv Exp Med Biol. 2013;788:103–8. doi: 10.1007/978-94-007-6627-3_16.
    1. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med. 2006;34(2):293–9. doi: 10.1097/01.CCM.0000198528.56397.4F.
    1. Boeck L, Eggimann P, Smyrnios N, Pargger H, Thakkar N, Siegemund M, et al. The Sequential Organ Failure Assessment score and copeptin for predicting survival in ventilator-associated pneumonia. J Crit Care. 2012;27(5):523.e1–9. doi: 10.1016/j.jcrc.2011.07.081.
    1. Krüger S, Ewig S, Kunde J, Hanschmann A, Marre R, Suttorp N, et al. C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. J Antimicrob Chemother. 2009;64(1):159–62. doi: 10.1093/jac/dkp148.
    1. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care. 2008;12(1):R11. doi: 10.1186/cc6780.
    1. Zhao YF, Lin Y, Zhang WG. [Clinical significance of serum copeptin in patients with community-acquired pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2009;32(12):911–4.
    1. Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F. Pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. ClinChem. 2007;53(15):2193–201. doi: 10.1373/clinchem.2007.085688.
    1. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058–67. doi: 10.1378/chest.06-2336.
    1. Potocki M, Breidthardt T, Mueller A, Reichlin T, Socrates T, Arenja N, et al. Copeptin and risk stratification in patients with acute dyspnea. Crit Care. 2010;14(6):R213. doi: 10.1186/cc9336.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa